Medinet: (Progress of disclosure matters) Taiwanese regulatory authorities have approved the provision of γδT cell therapy at new medical institutions (progress of licensing agreement with Medigen Biotechnology Corp.)
Medinet: Financial results briefing materials for the 2nd quarter of the fiscal year ending 2024/9
Medinet: Confirmation letter
Medinet: Quarterly Report - 29th Quarter 2nd Quarter (2024/01/01 to 2024/03/31)
Medinet: Notice Concerning the Recording of Non-Operating Income and Non-Operating Expenses
Medinet: Summary of financial results for the 2nd quarter of 2024
Medinet: Summary of financial results for the 2nd quarter of the fiscal year ending September 2024 [Japanese GAAP] (unconsolidated)
Medinet: Notice regarding the monthly exercise status of the 19th Stock Acquisition Rights (with exercise price amendment clause) through third-party allotment
Medinet: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Medinet: (Progress of disclosure matters) Taiwan regulatory authorities approve provision of gamma-delta T cell therapy at new medical institutions
Medinet: Notice regarding the monthly exercise status of the 19th Stock Acquisition Rights (with exercise price amendment clause) through third party allotment
Medinet: (Changes in disclosure matters) Changes in the use of funds and planned expenditure periods relating to the issuance of stock acquisition rights through third-party allotment
Medinet: Notice regarding the monthly exercise status of the 19th Stock Acquisition Rights (with exercise price amendment clause) through third party allotment
Medinet: (Progress of disclosure matters) Taiwan regulatory authorities approve provision of gamma-delta T cell therapy at new medical institutions
Medinet: Confirmation
Medinet: Quarterly Report - 29th Quarter 1st Quarter (2023/10/01 - 2023/12/31)
Medinet: Summary of Financial Results for the first quarter 2024
Medinet: Notice Concerning the Recording of Non-Operating Income and Non-Operating Expenses
Medinet: Summary of financial results for the 1st quarter of the fiscal year ending September 2024 [Japanese GAAP] (unconsolidated)
Medinet: Start contract manufacturing of new cell-processed products using our patented technology
No Data